Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect-Reference-Cited by-同舟云学术

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

Published:2006-01-23 Issue:5 Volume:37 Page:455-461
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Dasgupta R K,Rule S,Johnson P,Davies J,Burnett A,Poynton C,Wilson K,Smith G M,Jackson G,Richardson C,Wareham E,Stars A C,Tollerfield S M,Morgan G J

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705271.pdf

Reference27 articles.

1. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

3. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

4. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683–689.

5. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spleen-targeted delivery systems and strategies for spleen-related diseases;Journal of Controlled Release;2024-06

2. Chemotherapeutic Agents Used in Stem Cell Transplant;Basics of Hematopoietic Stem Cell Transplant;2023

3. Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome;Blood Advances;2020-11-19

4. Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan;Journal of Oncology Pharmacy Practice;2020-06-03

5. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia – update of single center study;Neoplasma;2017